Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 31, 2026, 12:52 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1177–1200 of 2,690 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Normal saline solution Clear all
Completed Phase 2Phase 3 Interventional Accepts healthy volunteers

The Efficacy and Molecular Mechanism of Botulinum Toxin in the Reduction of Breast Reduction Mammoplasty Scar Formation

NCT03887377
View directory record Official record
Conditions
Scar, Hypertrophic Scar, Mammary Disorder
Interventions
Botulinum Toxins, Normal saline
Drug · Other
Lead sponsor
Henry Ford Health System
Other
Eligibility
18 Years to 65 Years · Female only
Enrollment
22 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2024
U.S. locations
1
States / cities
Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Jun 15, 2025 · Synced Oct 31, 2026, 12:52 AM EDT
Terminated Phase 1 Interventional

L-Carnitine Administration in Early Sepsis

NCT01193777
View directory record Official record
Conditions
Septic Shock
Interventions
L-Carnitine, Normal Saline
Drug
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years and older
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
2
States / cities
Jackson, Mississippi • Charlotte, North Carolina
Source: ClinicalTrials.gov public record
Updated Apr 22, 2022 · Synced Oct 31, 2026, 12:52 AM EDT
Not yet recruiting Phase 1Phase 2 Interventional

Intravenous Acetate as an Adjunctive Treatment for Alcohol Withdrawal in Hospitalized Patients

NCT07810946
View directory record Official record
Conditions
Alcohol Withdrawal, Alcohol Abstinence, Alcohol Use Disorder
Interventions
Sodium Acetate, Placebo
Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
21 Years and older
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Oct 30, 2026 · Synced Oct 31, 2026, 12:52 AM EDT
Completed Phase 3 Interventional Results available

Use of Dexmedetomidine to Reduce Emergence Delirium Incident in Children

NCT00857727
View directory record Official record
Conditions
Agitation, Anesthesia, Pediatrics
Interventions
Dexmedetomidine, Saline
Drug
Lead sponsor
St. Luke's-Roosevelt Hospital Center
Other
Eligibility
6 Months to 17 Years
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Nov 27, 2018 · Synced Oct 31, 2026, 12:52 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Sculptra Aesthetic for the Treatment of Upper Knee Skin Laxity

NCT03487172
View directory record Official record
Conditions
Lax Skin, Knee
Interventions
poly-L-lactic acid to right knee, poly-L-lactic acid to left knee
Device
Lead sponsor
Goldman, Butterwick, Fitzpatrick and Groff
Other
Eligibility
30 Years to 65 Years · Female only
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated May 3, 2019 · Synced Oct 31, 2026, 12:52 AM EDT
Terminated Phase 3 Interventional Accepts healthy volunteers

A Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age

NCT05085366
View directory record Official record
Conditions
Cytomegalovirus Infection
Interventions
mRNA-1647, Placebo
Biological
Lead sponsor
ModernaTX, Inc.
Industry
Eligibility
16 Years to 40 Years · Female only
Enrollment
7,454 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2025
U.S. locations
181
States / cities
Birmingham, Alabama • Dothan, Alabama • Guntersville, Alabama + 141 more
Source: ClinicalTrials.gov public record
Updated Dec 15, 2025 · Synced Oct 31, 2026, 12:52 AM EDT
Completed Phase 2 Interventional Results available

Study to Evaluate the Effect on Parameters of Systemic Inflammation and Disease Outcomes and Safety of RPH-104 in Subjects With Acute ST-elevation Myocardial Infarction

NCT04463251
View directory record Official record
Conditions
Acute ST Segment Elevation Myocardial Infarction
Interventions
RPH-104 80 mg, Placebo
Biological · Drug
Lead sponsor
R-Pharm Overseas, Inc.
Industry
Eligibility
18 Years and older
Enrollment
102 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
3
States / cities
Cleveland, Ohio • Charlottesville, Virginia • Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated Jun 24, 2024 · Synced Oct 31, 2026, 12:52 AM EDT
Enrolling by invitation Phase 2 Interventional

Immunotherapy for Neurological Post-Acute Sequelae of SARS-CoV-2

NCT05350774
View directory record Official record
Conditions
Systemic Inflammation, Neuroinflammation, Microvascular Thrombosis
Interventions
IV normal saline, IV immunoglobulin
Drug
Lead sponsor
National Institute of Neurological Disorders and Stroke (NINDS)
NIH
Eligibility
18 Years to 100 Years
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 26, 2026 · Synced Oct 31, 2026, 12:52 AM EDT
Completed Phase 2 Interventional Results available

A Study to Determine the Efficacy and Safety of Luspatercept in Adults With Non Transfusion Dependent Beta (β)-Thalassemia

NCT03342404
View directory record Official record
Conditions
Thalassemia
Interventions
Luspatercept, Placebo, Best Supportive Care (BSC)
Drug · Other
Lead sponsor
Celgene
Industry
Eligibility
18 Years and older
Enrollment
145 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
4
States / cities
Los Angeles, California • Oakland, California • Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Dec 20, 2023 · Synced Oct 31, 2026, 12:52 AM EDT
Completed Not applicable Interventional

Local Anesthetic Infiltration and Infusion for Pain Control After Hip Replacement

NCT01409278
View directory record Official record
Conditions
Osteoarthritis
Interventions
Ropivacaine infiltration and saline infusion., Ropivacaine infiltration and infusion., Normal Saline
Procedure
Lead sponsor
Trinity Health Of New England
Other
Eligibility
18 Years to 80 Years
Enrollment
105 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
1
States / cities
Hartford, Connecticut
Source: ClinicalTrials.gov public record
Updated Aug 4, 2011 · Synced Oct 31, 2026, 12:52 AM EDT
Completed Not applicable Interventional Results available

Trial of Glutamine and Antioxidant Supplementation in Critically Ill Patients

NCT00133978
View directory record Official record
Conditions
Critical Illness, Sepsis, Multiple Organ Failure
Interventions
Glutamine, Antioxidants, Glutamine + Antioxidants, Placebo
Other
Lead sponsor
Daren K. Heyland
Other
Eligibility
18 Years and older
Enrollment
1,223 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2012
U.S. locations
5
States / cities
Aurora, Colorado • Louisville, Kentucky • Dayton, Ohio + 2 more
Source: ClinicalTrials.gov public record
Updated Jan 7, 2021 · Synced Oct 31, 2026, 12:52 AM EDT
Completed Phase 1 Interventional

Chemotherapy, Radiation Therapy, and Vaccine Therapy With Basiliximab in Treating Patients With Glioblastoma Multiforme That Has Been Removed by Surgery

NCT00626015
View directory record Official record
Conditions
Malignant Neoplasms of Brain
Interventions
PEP-3-KLH conjugate vaccine, daclizumab, temozolomide, placebo, PEP-3-KLH
Biological · Drug · Other
Lead sponsor
John Sampson
Other
Eligibility
18 Years to 120 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2013
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Jan 21, 2016 · Synced Oct 31, 2026, 12:52 AM EDT
Completed Phase 1Phase 2 Interventional

A Randomized Study to Evaluate the Safety and Efficacy of Various Doses of STP705 in Subjects With Hypertrophic Scar

NCT02956317
View directory record Official record
Conditions
Hypertrophic Scar
Interventions
STP705, Placebo
Drug
Lead sponsor
Sirnaomics
Industry
Eligibility
18 Years to 60 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
Cypress, California
Source: ClinicalTrials.gov public record
Updated Nov 24, 2021 · Synced Oct 31, 2026, 12:52 AM EDT
Terminated Phase 3 Interventional Accepts healthy volunteers Results available

Continuous Erector Spinae Block Versus Continuous Paravertebral Block

NCT03768440
View directory record Official record
Conditions
Pain, Postoperative
Interventions
continuous erector spinae block (ESB), continuous paravertebral block (PVB), Ropivacaine
Procedure · Drug
Lead sponsor
Boston Children's Hospital
Other
Eligibility
1 Month to 12 Years
Enrollment
34 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2025
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 13, 2026 · Synced Oct 31, 2026, 12:52 AM EDT
Completed Phase 2 Interventional

Study to Evaluate NVC-422 for Urinary Catheter Blockage and Encrustation

NCT01243125
View directory record Official record
Conditions
Urinary Catheter Blockage and Encrustation
Interventions
NVC-422, 0.2%, Sterile normal saline, 0.9%
Drug
Lead sponsor
NovaBay Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
67 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
8
States / cities
Downey, California • Naples, Florida • West Orange, New Jersey + 5 more
Source: ClinicalTrials.gov public record
Updated Aug 7, 2014 · Synced Oct 31, 2026, 12:52 AM EDT
Terminated Not applicable Interventional Accepts healthy volunteers Results available

Jet Injection of 1% Buffered Lidocaine Versus Topical EMLA for Local Anesthesia Before Lumbar Puncture in Children

NCT01628874
View directory record Official record
Conditions
Lumbar Puncture, Topical Analgesia
Interventions
J-Tip, EMLA, Lidocaine
Device · Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
Up to 18 Years
Enrollment
66 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2016
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Jun 21, 2019 · Synced Oct 31, 2026, 12:52 AM EDT
Recruiting Phase 2 Interventional

High vs. Standard Dose Influenza Vaccines in Lung Transplant (Repeater)

NCT07192458
View directory record Official record
Conditions
Immunization; Infection|Transplantation Infection|Influenza, Influenza
Interventions
Fluzone High Dose Inactivated Influenza Vaccine, Fluzone Standard Dose Inactivated Influenza Vaccine
Biological
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Oct 21, 2026 · Synced Oct 31, 2026, 12:52 AM EDT
Completed Phase 4 Interventional Results available

Nicotine Administration and Post-operative Opioid Use With Bariatric Surgery

NCT01194089
View directory record Official record
Conditions
Pain, Postoperative
Interventions
Nasal Nicotine Spray, Nasal Normal Saline Spray
Drug
Lead sponsor
Toby Weingarten
Other
Eligibility
18 Years to 60 Years · Female only
Enrollment
95 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jul 9, 2015 · Synced Oct 31, 2026, 12:52 AM EDT
Completed Phase 2 Interventional Results available

A Study of LJPC-401 for the Treatment of Iron Overload in Adult Patients With Hereditary Hemochromatosis

NCT03395704
View directory record Official record
Conditions
Hereditary Hemochromatosis
Interventions
LJPC-401, Placebo
Drug
Lead sponsor
La Jolla Pharmaceutical Company
Industry
Eligibility
18 Years and older
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
18
States / cities
North Little Rock, Arkansas • Los Angeles, California • Palo Alto, California + 15 more
Source: ClinicalTrials.gov public record
Updated Jun 9, 2022 · Synced Oct 31, 2026, 12:52 AM EDT
Terminated Phase 2Phase 3 Interventional Results available

Application of Indocyanine Green Angiography for Closed Operative Calcaneus Fractures

NCT01693484
View directory record Official record
Conditions
Fractures, Comminuted, Surgical Wound Dehiscence, Necrosis
Interventions
ICG (Indocyanine Green)
Drug
Lead sponsor
Louisiana State University Health Sciences Center Shreveport
Other
Eligibility
18 Years to 65 Years
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
Shreveport, Louisiana
Source: ClinicalTrials.gov public record
Updated Jun 20, 2017 · Synced Oct 31, 2026, 12:52 AM EDT
Completed Phase 1 Interventional

Dose-finding, Pharmacokinetics, and Safety of VABOMERE in Pediatric Subjects With Bacterial Infections

NCT02687906
View directory record Official record
Conditions
Bacterial Infections
Interventions
Vabomere
Drug
Lead sponsor
Rempex (a wholly owned subsidiary of Melinta Therapeutics, LLC)
Industry
Eligibility
Up to 17 Years
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2026
U.S. locations
9
States / cities
Little Rock, Arkansas • Los Angeles, California • Orange, California + 6 more
Source: ClinicalTrials.gov public record
Updated Aug 17, 2026 · Synced Oct 31, 2026, 12:52 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Phase 1 Study to Assess the Safety of NLY01 in Healthy Subjects

NCT03672604
View directory record Official record
Conditions
Safety and Tolerability in Healthy Volunteers
Interventions
NLY01
Drug
Lead sponsor
Neuraly, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
96 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Sep 30, 2019 · Synced Oct 31, 2026, 12:52 AM EDT
Recruiting Phase 2 Interventional Accepts healthy volunteers

Changes in Hemorrhage With Prophylactic Oxytocin for Dilation and Evacuation

NCT06141447
View directory record Official record
Conditions
Hemorrhage
Interventions
Oxytocin + normal saline, Normal saline
Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years to 55 Years · Female only
Enrollment
150 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2026
U.S. locations
1
States / cities
Denver, Colorado
Source: ClinicalTrials.gov public record
Updated Dec 10, 2024 · Synced Oct 31, 2026, 12:52 AM EDT
Terminated Phase 3 Interventional

Study of the Efficacy and Safety of Tezosentan in Patients With Pre-operative Pulmonary Hypertension, Due to Left Heart Disease, Undergoing Open Heart Surgery

NCT00458276
View directory record Official record
Conditions
Heart Diseases, Hypertension, Pulmonary
Interventions
tezosentan, placebo
Drug
Lead sponsor
Idorsia Pharmaceuticals Ltd.
Industry
Eligibility
18 Years and older
Enrollment
274 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
9
States / cities
Stanford, California • New York, New York • Durham, North Carolina + 5 more
Source: ClinicalTrials.gov public record
Updated Jul 9, 2018 · Synced Oct 31, 2026, 12:52 AM EDT